Skip to main content
Top
Published in:

Open Access 14-05-2025 | Bullous Pemphigoid | Original Research

Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts

Authors: Calvin N. Ho, Lila Bahadori, Marc Yale, Naomi Bishop, Caroline Roberts, Oren Meyers, Julie Bailey, Neil J. Korman

Published in: Dermatology and Therapy | Issue 7/2025

Login to get access

Abstract

Introduction

Bullous pemphigoid (BP) is a chronic autoimmune blistering disorder that imposes a significant health-related quality of life burden on the lives of patients; however, there are limited data on patient experiences.

Methods

We conducted qualitative open-ended interviews of patients from the USA, Spain, and France, to understand BP symptoms and impacts, and develop a conceptual model. Adults with a confirmed BP diagnosis were included. Patients with pemphigus or drug-induced BP were excluded.

Results

Thirty participants were recruited. The mean (standard deviation) age was 63.6 (16.0) years. Eleven signs and symptoms and 24 impacts were reported; six signs and symptoms, and 13 impacts affected ≥ 50% of participants with an average disturbance rating of ≥ 5 out of 10 (scale of 0 to 10 [0, not disturbing; 10, extremely disturbing]). All participants reported typical signs and symptoms of classic and/or mucosal BP. Overall, five of six salient symptoms and four of 13 salient impacts had an average disturbance rating of ≥ 7.5/10, indicating that BP is highly burdensome. Regarding corticosteroids, participants expressed a strong desire to avoid taking them again, due to the associated unwanted side effects.

Conclusion

The conceptual model presented here can be the basis for endpoint selection in studies of new therapies for BP.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Patient Experiences of Bullous Pemphigoid: Symptoms and Health-Related Quality of Life Impacts
Authors
Calvin N. Ho
Lila Bahadori
Marc Yale
Naomi Bishop
Caroline Roberts
Oren Meyers
Julie Bailey
Neil J. Korman
Publication date
14-05-2025
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 7/2025
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-025-01424-z

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more